These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35776987)

  • 1. Identification of prognostic and immunotherapy-related eRNA ID2-AS1 in bladder cancer.
    Zhang L; Ding D; Liu J; Liu J; Wang N; Liu J
    Medicine (Baltimore); 2022 Jul; 101(26):e29759. PubMed ID: 35776987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
    Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
    Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer.
    Ding K; Zheng Z; Han Y; Huang X
    Cell Cycle; 2022 Dec; 21(23):2533-2549. PubMed ID: 35894701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer.
    Wu Y; Zhang L; He S; Guan B; He A; Yang K; Gong Y; Li X; Zhou L
    Aging (Albany NY); 2020 Nov; 12(22):23306-23325. PubMed ID: 33221763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the immune related lncRNAs in bladder cancer to aid immunotherapy.
    Xiao Y; Dong Y; Yu T; Wang R; Gao Y; Li S; Nong S; Li W
    Front Immunol; 2022; 13():941189. PubMed ID: 36091015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncogenic role of TFAP2A in bladder urothelial carcinoma via a novel long noncoding RNA TPRG1-AS1/DNMT3A/CRTAC1 axis.
    He J; Dong C; Zhang H; Jiang Y; Liu T; Man X
    Cell Signal; 2023 Feb; 102():110527. PubMed ID: 36410635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA TMPO-AS1 promotes proliferation and migration in bladder cancer.
    He YC; Bi YG; Jiang L
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8740-8746. PubMed ID: 32964962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA ID2-AS1 suppresses tumor metastasis by activating the HDAC8/ID2 pathway in hepatocellular carcinoma.
    Zhou Y; Huan L; Wu Y; Bao C; Chen B; Wang L; Huang S; Liang L; He X
    Cancer Lett; 2020 Jan; 469():399-409. PubMed ID: 31730902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
    Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of cuproptosis-related long non-coding RNA and construction of a novel prognostic signature for bladder cancer: An observational study.
    Ye Z; Liu C; Wu S; Jin X; Lin H; Wang T; Zheng Q; Guo Z
    Medicine (Baltimore); 2024 May; 103(18):e38005. PubMed ID: 38701267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
    Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
    Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
    Qiu Y; Ye W; Wang C; Zang J
    Aging (Albany NY); 2023 Nov; 15(22):13312-13328. PubMed ID: 38015710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA MAFG-AS1 Promotes the Progression of Bladder Cancer by Targeting the miR-143-3p/COX-2 Axis.
    Li D; Zhong S; Zhu Z; Jiang X; Zhang J; Gu J; Chen F
    Pathobiology; 2020; 87(6):345-355. PubMed ID: 33238264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Integrative Analysis Revealing ZFHX4-AS1 as a Novel Prognostic Biomarker Correlated with Immune Infiltrates in Ovarian Cancer.
    Huang C; Cui H; Lang X; Zhao F
    J Immunol Res; 2022; 2022():9912732. PubMed ID: 35795530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
    Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
    Front Immunol; 2022; 13():916800. PubMed ID: 35860239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA TP73-AS1 predicts the prognosis of bladder cancer patients and functions as a suppressor for bladder cancer by EMT pathway.
    Tuo Z; Zhang J; Xue W
    Biochem Biophys Res Commun; 2018 May; 499(4):875-881. PubMed ID: 29625110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Two-eRNA-Based Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.
    Wang L; Zhou SQ; Zhou Y; Lu JX
    J Immunol Res; 2022; 2022():8069858. PubMed ID: 35600050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA ZEB1-AS1 regulates miR-200b/FSCN1 signaling and enhances migration and invasion induced by TGF-β1 in bladder cancer cells.
    Gao R; Zhang N; Yang J; Zhu Y; Zhang Z; Wang J; Xu X; Li Z; Liu X; Li Z; Li J; Kong C; Bi J
    J Exp Clin Cancer Res; 2019 Mar; 38(1):111. PubMed ID: 30823924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.